Quartz·1 min read·medium
AstraZeneca stock plunges after late-stage heart drug trial misses its target
✦AI Summary
AstraZeneca's stock value dropped by $27 billion following the failure of its Wainua drug trial. The medication failed to meet its primary goal of reducing cardiovascular deaths and heart-related events.
The British drugmaker lost roughly $27 billion in market value after Wainua failed to reduce cardiovascular deaths and recurring heart events
businesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in